Suit By 23 Tenured Faculty Members Against USC Illustrates Changes In Biomedical Research Culture

Sidebar: "The Financing of Medical Schools" - For Further Information A DEMOTION? The plaintiffs’ attorney, Jeffrey Kramer, notes that the reduction in their contract term was not accompanied by a reduction in their duties. Twenty-three tenured members of the basic science faculty at the University of Southern California (USC) School of Medicine have sued the Los Angeles-based university for $54 million, alleging that USC has breached their contracts and is violating established princip

Written byRobert Finn
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Sidebar: "The Financing of Medical Schools" - For Further Information

In June 1995, the USC administration, citing financial difficulties at the medical school, switched all 108 members of the basic science faculty from 12-month appointments to nine-month appointments, reducing their salaries by 25 percent. Members of the basic science faculty teach preclinical courses such as anatomy, biochemistry, and endocrinology to medical students. The basic science faculty is distinct from the clinical faculty, whose 12-month appointments will remain unaffected by the new policy.


MEGATRENDS: AAMC’s David Blake says "what’s at stake is the health of the biomedical research enterprise."
"In other schools, like arts and science schools, nine-month appointments are the rule, not the exception," notes David A. Blake, senior vice president for research of the Washington, D.C.-based AAMC. Indeed, faculty members at USC's other schools have long been on academic-year contracts.

"The economic megatrends running through the world, one of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies